461 related articles for article (PubMed ID: 33758861)
1. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants.
Tchesnokova V; Kulakesara H; Larson L; Bowers V; Rechkina E; Kisiela D; Sledneva Y; Choudhury D; Maslova I; Deng K; Kutumbaka K; Geng H; Fowler C; Greene D; Ralston J; Samadpour M; Sokurenko E
bioRxiv; 2021 Mar; ():. PubMed ID: 33758861
[TBL] [Abstract][Full Text] [Related]
2. Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants.
Tchesnokova V; Kulasekara H; Larson L; Bowers V; Rechkina E; Kisiela D; Sledneva Y; Choudhury D; Maslova I; Deng K; Kutumbaka K; Geng H; Fowler C; Greene D; Ralston J; Samadpour M; Sokurenko E
J Clin Microbiol; 2021 Oct; 59(11):e0092121. PubMed ID: 34379531
[TBL] [Abstract][Full Text] [Related]
3. Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.
Tragni V; Preziusi F; Laera L; Onofrio A; Mercurio I; Todisco S; Volpicella M; De Grassi A; Pierri CL
EPMA J; 2022 Mar; 13(1):149-175. PubMed ID: 35013687
[TBL] [Abstract][Full Text] [Related]
4. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
5. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
Deng X; Garcia-Knight MA; Khalid MM; Servellita V; Wang C; Morris MK; Sotomayor-González A; Glasner DR; Reyes KR; Gliwa AS; Reddy NP; Sanchez San Martin C; Federman S; Cheng J; Balcerek J; Taylor J; Streithorst JA; Miller S; Sreekumar B; Chen PY; Schulze-Gahmen U; Taha TY; Hayashi JM; Simoneau CR; Kumar GR; McMahon S; Lidsky PV; Xiao Y; Hemarajata P; Green NM; Espinosa A; Kath C; Haw M; Bell J; Hacker JK; Hanson C; Wadford DA; Anaya C; Ferguson D; Frankino PA; Shivram H; Lareau LF; Wyman SK; Ott M; Andino R; Chiu CY
Cell; 2021 Jun; 184(13):3426-3437.e8. PubMed ID: 33991487
[TBL] [Abstract][Full Text] [Related]
6. Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants.
Spratt AN; Kannan SR; Woods LT; Weisman GA; Quinn TP; Lorson CL; Sönnerborg A; Byrareddy SN; Singh K
Comput Struct Biotechnol J; 2021; 19():3799-3809. PubMed ID: 34188776
[TBL] [Abstract][Full Text] [Related]
7. The Emergence of the New P.4 Lineage of SARS-CoV-2 With Spike L452R Mutation in Brazil.
Bittar C; Possebon FS; Ullmann LS; Geraldini DB; da Costa VG; de Almeida LGP; da S Sanches PR; Nascimento-Júnior NM; Cilli EM; Artico Banho C; Campos GRF; Ferreira HL; Sacchetto L; da Silva GCD; Parra MCP; Moraes MM; da Costa PI; Vasconcelos ATR; Spilki FR; Nogueira ML; Rahal P; Araujo JP
Front Public Health; 2021; 9():745310. PubMed ID: 34660520
[TBL] [Abstract][Full Text] [Related]
8. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation.
Deng X; Garcia-Knight MA; Khalid MM; Servellita V; Wang C; Morris MK; Sotomayor-González A; Glasner DR; Reyes KR; Gliwa AS; Reddy NP; Martin CSS; Federman S; Cheng J; Balcerek J; Taylor J; Streithorst JA; Miller S; Kumar GR; Sreekumar B; Chen PY; Schulze-Gahmen U; Taha TY; Hayashi J; Simoneau CR; McMahon S; Lidsky PV; Xiao Y; Hemarajata P; Green NM; Espinosa A; Kath C; Haw M; Bell J; Hacker JK; Hanson C; Wadford DA; Anaya C; Ferguson D; Lareau LF; Frankino PA; Shivram H; Wyman SK; Ott M; Andino R; Chiu CY
medRxiv; 2021 Mar; ():. PubMed ID: 33758899
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.
Cherian S; Potdar V; Jadhav S; Yadav P; Gupta N; Das M; Rakshit P; Singh S; Abraham P; Panda S; Team N
Microorganisms; 2021 Jul; 9(7):. PubMed ID: 34361977
[TBL] [Abstract][Full Text] [Related]
10. SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity.
Neerukonda SN; Vassell R; Lusvarghi S; Wang R; Echegaray F; Bentley L; Eakin AE; Erlandson KJ; Katzelnick LC; Weiss CD; Wang W
bioRxiv; 2021 Nov; ():. PubMed ID: 34790980
[TBL] [Abstract][Full Text] [Related]
11. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease.
Perez-Gomez R
J Dev Biol; 2021 Dec; 9(4):. PubMed ID: 34940505
[TBL] [Abstract][Full Text] [Related]
12. The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R.
Mor O; Mandelboim M; Fleishon S; Bucris E; Bar-Ilan D; Linial M; Nemet I; Kliker L; Lustig Y; Israel National Consortium For Sars-CoV-Sequencing ; Mendelson ES; Zuckerman NS
Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452062
[TBL] [Abstract][Full Text] [Related]
13. The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera.
Li G; Zhou Z; Du P; Yu M; Li N; Xiong X; Huang H; Liu Z; Dai Q; Zhu J; Guo C; Wu S; Baptista-Hon DT; Miao M; Ming LW; Wu Y; Zeng F; Zhang CL; Zhang ED; Song H; Liu J; Lau JY; Xiang AP; Zhang K
Precis Clin Med; 2021 Sep; 4(3):149-154. PubMed ID: 35693215
[TBL] [Abstract][Full Text] [Related]
14. Molecular Dynamics Simulation Study of the Interaction between Human Angiotensin Converting Enzyme 2 and Spike Protein Receptor Binding Domain of the SARS-CoV-2 B.1.617 Variant.
Antony P; Vijayan R
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439910
[TBL] [Abstract][Full Text] [Related]
15. A Founder Effect Led Early SARS-CoV-2 Transmission in Spain.
Díez-Fuertes F; Iglesias-Caballero M; García-Pérez J; Monzón S; Jiménez P; Varona S; Cuesta I; Zaballos Á; Jiménez M; Checa L; Pozo F; Pérez-Olmeda M; Thomson MM; Alcamí J; Casas I
J Virol; 2021 Jan; 95(3):. PubMed ID: 33127745
[TBL] [Abstract][Full Text] [Related]
16. Insights into the structure and dynamics of SARS-CoV-2 spike glycoprotein double mutant L452R-E484Q.
Ahamad S; Hema K; Ahmad S; Kumar V; Gupta D
3 Biotech; 2022 Apr; 12(4):87. PubMed ID: 35265451
[TBL] [Abstract][Full Text] [Related]
17. Molecular Analysis of SARS-CoV-2 Circulating in Bangladesh during 2020 Revealed Lineage Diversity and Potential Mutations.
Parvin R; Afrin SZ; Begum JA; Ahmed S; Nooruzzaman M; Chowdhury EH; Pohlmann A; Paul SK
Microorganisms; 2021 May; 9(5):. PubMed ID: 34065789
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations.
Cocherie T; Zafilaza K; Leducq V; Marot S; Calvez V; Marcelin AG; Todesco E
Microorganisms; 2022 Dec; 11(1):. PubMed ID: 36677322
[TBL] [Abstract][Full Text] [Related]
19. Genomic Characterization of an Emerging SARS-CoV-2 Variant During the Early Second Wave of the SARS-CoV-2 Pandemic in Maharashtra, India.
Karyakarte RP; Das R; Joshi S; Jayaram A; Yanamandra S; Shende S; Taji N; Rane S; Bawale R; Chaudhari GP; Karekar B; Sakalkar SR; Tiwari RG; Jadhav MG
Cureus; 2023 Nov; 15(11):e48604. PubMed ID: 38090396
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429.
McCallum M; Bassi J; Marco A; Chen A; Walls AC; Iulio JD; Tortorici MA; Navarro MJ; Silacci-Fregni C; Saliba C; Agostini M; Pinto D; Culap K; Bianchi S; Jaconi S; Cameroni E; Bowen JE; Tilles SW; Pizzuto MS; Guastalla SB; Bona G; Pellanda AF; Garzoni C; Van Voorhis WC; Rosen LE; Snell G; Telenti A; Virgin HW; Piccoli L; Corti D; Veesler D
bioRxiv; 2021 Apr; ():. PubMed ID: 33821281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
